In the article “Prasugrel as Antiplatelet Therapy in Patients With Acute Coronary Syndromes or Undergoing Percutaneous Coronary Intervention” (October 2010:45–54), Table 1 (on page 46) incorrectly lists the antiplatelet agent Angiomax as a glycoprotein IIb/IIIa inhibitor; Angiomax is a direct thrombin inhibitor.

You do not currently have access to this content.